June 2024 Top 25 Drug Classes and Drugs by Cost





Annual Utilization 2021 to 2023

- Top 25 Classes
- Top 25 Drugs




Annual Utilization - Background

Methodology

- Pharmacy Point-of-Sale Claims
- Date Range: 1/1/2021 to 12/31/2023
- Fee-for-Service and Managed Care Claims




Annual Utilization



Washington State Health Care Authority

Annual Utilization





Top 25 Classes by Cost - Background

Apple Health Drug Class (e.g. ANTIDEPRESSANTS : TRICYCLIC AGENTS)

- Class The component before the " : "
 - > Example: ANTIDEPRESSANTS
 - > There 64 Classes as of 2023
- Subclass: The component after the ":"
 - Example: TRICYCLIC AGENTS
 - > Some drug classes do not contain a subclass (e.g. Cytokine & CAM Antagonists)
 - There were 494 Apple Health Drug Classes as of 2023

Top 25 classes were included based on total cost, inclusive of rebates.




Top 25 Classes by Cost – Highest Cost Drug Classes 2023

Apple Health Class	Net Paid	Net Paid PMPM
CYTOKINE AND CAM ANTAGONISTS	\$133,131,487	\$5.03
HIV	\$89,753,775	\$3.39
ANTIDIABETICS	\$70,713,233	\$2.67
ONCOLOGY AGENTS	\$62,525,679	\$2.36
ASTHMA AND COPD AGENTS	\$60,255,354	\$2.28
ANTIPSYCHOTICS / ANTIMANIC AGENTS	\$54,367,088	\$2.06
ADHD / ANTI-NARCOLEPSY	\$40,900,700	\$1.55
RESPIRATORY AGENTS	\$40,621,994	\$1.54
ENDOCRINE AND METABOLIC AGENTS	\$40,144,170	\$1.52
SUBSTANCE USE DISORDER	\$39,998,839	\$1.51
ANTICONVULSANTS	\$33,309,701	\$1.26
ATOPIC DERMATITIS AGENTS	\$25,525,051	\$0.97
ANTIVIRALS	\$21,372,504	\$0.81
NEUROMUSCULAR AGENTS	\$20,063,789	\$0.76
PULMONARY HYPERTENSION AGENTS	\$18,752,807	\$0.71
MULTIPLE SCLEROSIS AGENTS	\$16,369,219	\$0.62
ANTIHYPERTENSIVES	\$16,324,506	\$0.62
GASTROINTESTINAL AGENTS	\$15,730,948	\$0.59
ANTIDEPRESSANTS	\$14,493,204	\$0.55
ANALGESICS	\$13,748,650	\$0.52
ANTIBIOTICS	\$13,733,677	\$0.52
HEMATOLOGICAL AGENTS	\$12,287,608	\$0.46
DERMATOLOGICS	\$11,419,916	\$0.43
ALLERGY	\$10,928,882	\$0.41
CONTRACEPTIVES	\$10,461,889	\$0.40



Top 25 Classes by Cost – PMPM Increase 2021 to 2023


Increase in PMPM from 2021 to 2023





Top 25 Classes by Cost – PMPM Increase 2021 to 2023


Increase in PMPM from 2021 to 2023





Top 25 Classes by Cost – PMPM Percent Increase 2021 to 2023


Percent Increase in PMPM from 2021 to 2023





Top 25 Classes by Cost – PMPM Decrease 2021 to 2023


Decrease in PMPM from 2021 to 2023





Top 25 Classes by Cost – PMPM Decrease 2021 to 2023


Decrease in PMPM from 2021 to 2023





Top 25 Classes by Cost – PMPM Percent Decrease 2021 to 2023

Percent Decrease in PMPM from 2021 to 2023





Top 25 Classes by Cost – Summary Of Drug Cost

Of the top 25 classes by Cost

- 15 classes had increases in PMPM from 2021 to 2023
 - > The classes with the greatest increases in PMPM includes:
 - Cytokine & CAM Antagonists, Antidiabetics, Asthma and COPD agents, Atopic Dermatitis Agents, Endocrine and Metabolic Agents, Oncology Agents, Neuromusucular Agents, Respiratory Agents, Antipsychotics/Antimanic Agents, Substance Use Disorder, Hematological Agents, and Allergy
- 10 classes had decreases in PMPM from 2021 to 2023
 - The classes with decreases in PMPM includes:
 - Antidepressants, Antivirals, Contraceptives, Dermatologics, Analgesics, and Gastrointestinal Agents



Top 25 Classes by Cost – Number of Clients 2023

Apple Health Class	Clients	Claims	Net Paid/Claim
ANTIBIOTICS	527,717	987,340	\$13.91
ANALGESICS	442,472	1,620,796	\$8.48
ANTIDEPRESSANTS	268,372	1,580,952	\$9.17
GASTROINTESTINAL AGENTS	241,600	934,372	\$16.84
ANTIHYPERTENSIVES	210,263	1,173,854	\$13.91
ALLERGY	207,003	697,139	\$15.68
ASTHMA AND COPD AGENTS	189,360	877,491	\$68.67
DERMATOLOGICS	155,435	329,828	\$34.62
ANTICONVULSANTS	139,268	992,884	\$33.55
ANTIDIABETICS	93,943	817,150	\$86.54
ADHD / ANTI-NARCOLEPSY	87,236	649,427	\$62.98
ENDOCRINE AND METABOLIC AGENTS	78,969	495,461	\$81.02
ANTIPSYCHOTICS / ANTIMANIC AGENTS	70,461	581,868	\$93.44
CONTRACEPTIVES	67,864	200,927	\$52.07
SUBSTANCE USE DISORDER	59,815	350,388	\$114.16
ANTIVIRALS	46,186	120,983	\$176.66
HIV	8,040	66,502	\$1,349.64
HEMATOLOGICAL AGENTS	7,398	37,181	\$330.48
CYTOKINE AND CAM ANTAGONISTS	7,080	49,016	\$2,716.08
ONCOLOGY AGENTS	6,161	35,699	\$1,751.47
ATOPIC DERMATITIS AGENTS	4,410	15,983	\$1,597.01
MULTIPLE SCLEROSIS AGENTS	767	5,803	\$2,820.82
NEUROMUSCULAR AGENTS	538	3,141	\$6,387.71
PULMONARY HYPERTENSION AGENTS	495	5,479	\$3,422.67
RESPIRATORY AGENTS	328	3,190	\$12,734.17



Top 25 Classes by Cost – Number and Percent Change of Clients 2021 to 2023

Apple Health Class	Clients 2021	Clients 2023	Clients % Change
ATOPIC DERMATITIS AGENTS	2,536	4,410	73.9%
NEUROMUSCULAR AGENTS	404	538	33.2%
ANTIBIOTICS	407,510	527,717	29.5%
SUBSTANCE USE DISORDER	46,824	59,815	27.7%
ADHD / ANTI-NARCOLEPSY	70,310	87,236	24.1%
CYTOKINE AND CAM ANTAGONISTS	5,847	7,080	21.1%
ANTIVIRALS	38,199	46,186	20.9%
ANTIDIABETICS	78,439	93,943	19.8%
HIV	6,813	8,040	18.0%
CONTRACEPTIVES	74,814	67,864	-9.3%



Top 25 Classes by Cost – Summary of Utilization

• Of the top 25 classes from 2021 to 2023

- 24 classes had an increase in client utilization
 - The classes with the greatest percent increase in clients include Atopic Dermatitis Agents, Neuromuscular Agents, Antibiotics, Substance Use Disorder, ADHD/ Anti-Narcolepsy, Cytokine & CAM Antagonists, Antivirals, and HIV
- The Contraceptives class was the only class with a decrease in client utilization
- ▶ The number of clients utilizing a class each year ranges from 328 to 527,717



Top 25 Drugs by Cost - Background

- Identified using label name
 - Examples include:
 - "fluoxetine"
 - "Prozac"
 - "Humira"
 - "Humira Pen"
 - "adalimumab-ADBM "

Top 25 drugs were included based on total cost, inclusive of rebates.




Top 25 Drugs by Cost - Highest Cost Drugs 2023

From Top 25 Classon	Label Name	Net Paid	Cliente	Net Paid	Net Paid/
From Top 25 Classes			Clients	РМРМ	Client
Cytokine & CAM	STELARA	\$45,250,593	616	\$1.71	\$73,459
Respiratory Agents	TRIKAFTA	\$36,238,919	238	\$1.37	\$152,264
HIV	BIKTARVY	\$24,558,241	1609	\$0.93	\$15,263
Atopic Dermatitis Agents	DUPIXENT	\$24,065,432	1509	\$0.91	\$15,948
Cytokine & CAM	HUMIRA PEN	\$19,739,640	3153	\$0.75	\$6,261
Antidiabetics	VICTOZA	\$16,612,388	18379	\$0.63	\$904
Substance Use Disorder	SUBOXONE	\$16,515,334	22478	\$0.62	\$735
Antivirals	MAVYRET	\$15,957,442	1443	\$0.60	\$11,059
HIV	TIVICAY	\$15,923,044	1694	\$0.60	\$9,400
ADHD/Anti-Narcolepsy	AMPHETAMINE/DEXTROAMPHETAMINE	\$14,083,723	35860	\$0.53	\$393
HIV	DESCOVY	\$12,275,361	1434	\$0.46	\$8,560
Antipsychotic/Antimanic Agents	INVEGA SUSTENNA	\$12,011,981	1767	\$0.45	\$6,798
Cytokine & CAM	SKYRIZI PEN	\$11,029,653	255	\$0.42	\$43,254
Antidiabetics	JARDIANCE	\$11,002,265	17866	\$0.42	\$616
Cytokine & CAM	TALTZ	\$10,995,659	273	\$0.42	\$40,277
Asthma and COPD Agents	ALBUTEROL SULFATE HFA	\$10,095,151	157633	\$0.38	\$64
Asthma and COPD Agents	FLUTICASONE PROPIONATE HFA	\$9,950,167	23981	\$0.38	\$415
ADHD/Anti-Narcolepsy	METHYLPHENIDATE HYDROCHLORIDE ER	\$9,874,277	20719	\$0.37	\$477
HIV	EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	\$9,708,453	3585	\$0.37	\$2,708
Cytokine & CAM	COSENTYX SENSOREADY PEN	\$9,684,654	384	\$0.37	\$25,220
Asthma and COPD Agents	BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE	\$8,048,033	11005	\$0.30	\$731
Pulmonary Arterial Hypertension	UPTRAVI	\$7,904,664	63	\$0.30	\$125,471
Substance Use Disorder	SUBLOCADE	\$7,891,277	1860	\$0.30	\$4,243
HIV	GENVOYA	\$7,716,781	424	\$0.29	\$18,200
Cytokine & CAM	RINVOQ	\$6,809,852	372	\$0.26	\$18,306

Washington State Health Care Authority

Top 25 Drugs by Cost – PMPM Increase 2021 to 2023

Increase in PMPM from 2021 to 2023





Top 25 Drugs by Cost – PMPM Increase 2021 to 2023


Increase in PMPM from 2021 to 2023



Washington State Health Care Authority

Top 25 Drugs by Cost – PMPM Percent Increase 2021 to 2023


Percent Increase in PMPM from 2021 to 2023





Top 25 Drugs by Cost – PMPM Decrease 2021 to 2023


Decrease in PMPM from 2021 to 2023



Washington State Health Care Authority

Top 25 Drugs by Cost – PMPM Decrease 2021 to 2023


Decrease in PMPM from 2021 to 2023





Top 25 Drugs by Cost – PMPM Percent Decrease 2021 to 2023

Percent Decrease in PMPM from 2021 to 2023





Top 25 Drugs by Cost – Summary Of Drug Spend

• Of the top 25 drugs by Cost

- 18 drugs had increases in PMPM from 2021 to 2023
 - > The drugs with the greatest increases in PMPM includes:
 - Stelara, Trikafta, Dupixent, Victoza, Skyrizi Pen, Biktarvy, Jardiance, and Sublocade
- 7 drugs had decreases in PMPM from 2021 to 2023
 - > The drugs with the greatest decreases in PMPM includes:
 - Methylphenidate hydrochloride ER, Mavyret, Genvoya, Cosentyx Sensoready Pen, Descovy, emtricitabine/tenofovir disoproxil fumarate and budesonide/formoterol fumarate.



Top 25 Drugs by Cost – Number of Clients 2023

From Ton 25 Closes	Labol Namo	Not Doid	Clients	Net Paid	Net Paid/
From Top 25 Classes	Label Name	Net Paid		РМРМ	Client
Pulmonary Arterial Hypertension	UPTRAVI	\$7,904,664	63	\$0.30	\$125,471
Respiratory Agents	TRIKAFTA	\$36,238,919	238	\$1.37	\$152,264
Cytokine & CAM	SKYRIZI PEN	\$11,029,653	255	\$0.42	\$43,254
Cytokine & CAM	TALTZ	\$10,995,659	273	\$0.42	\$40,277
Cytokine & CAM	RINVOQ	\$6,809,852	372	\$0.26	\$18,306
Cytokine & CAM	COSENTYX SENSOREADY PEN	\$9,684,654	384	\$0.37	\$25,220
HIV	GENVOYA	\$7,716,781	424	\$0.29	\$18,200
Cytokine & CAM	STELARA	\$45,250,593	616	\$1.71	\$73,459
HIV	DESCOVY	\$12,275,361	1434	\$0.46	\$8,560
Antivirals	MAVYRET	\$15,957,442	1443	\$0.60	\$11,059
Atopic Dermatitis Agents	DUPIXENT	\$24,065,432	1509	\$0.91	\$15,948
HIV	BIKTARVY	\$24,558,241	1609	\$0.93	\$15,263
HIV	TIVICAY	\$15,923,044	1694	\$0.60	\$9,400
Antipsychotic/Antimanic Agents	INVEGA SUSTENNA	\$12,011,981	1767	\$0.45	\$6,798
Substance Use Disorder	SUBLOCADE	\$7,891,277	1860	\$0.30	\$4,243
Cytokine & CAM	HUMIRA PEN	\$19,739,640	3153	\$0.75	\$6,261
HIV	EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	\$9,708,453	3585	\$0.37	\$2,708
Asthma and COPD Agents	BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE	\$8,048,033	11005	\$0.30	\$731
Antidiabetics	JARDIANCE	\$11,002,265	17866	\$0.42	\$616
Antidiabetics	VICTOZA	\$16,612,388	18379	\$0.63	\$904
ADHD/Anti-Narcolepsy	METHYLPHENIDATE HYDROCHLORIDE ER	\$9,874,277	20719	\$0.37	\$477
Substance Use Disorder	SUBOXONE	\$16,515,334	22478	\$0.62	\$735
Asthma and COPD Agents	FLUTICASONE PROPIONATE HFA	\$9,950,167	23981	\$0.38	\$415
ADHD/Anti-Narcolepsy	AMPHETAMINE/DEXTROAMPHETAMINE	\$14,083,723	35860	\$0.53	\$393
Asthma and COPD Agents	ALBUTEROL SULFATE HFA	\$10,095,151	157633	\$0.38	\$64

Washington State Health Care Authority

Top 25 Drugs by Cost – Number and Percent Change of Clients 2021 to 2023

From Top 25 Classes	Label Name	Clients 2021	Clients 2023	Change	% Change
Cytokine & CAM	SKYRIZI PEN	45	255	210	466.7%
Substance Use Disorder	SUBLOCADE	433	1,860	1,427	329.6%
Cytokine & CAM	RINVOQ	136	372	236	173.5%
Atopic Dermatitis Agents	DUPIXENT	691	1,509	818	118.4%
HIV	BIKTARVY	828	1,609	781	94.3%
Antidiabetics	VICTOZA	9,579	18,379	8,800	91.9%
Antidiabetics	JARDIANCE	9,329	17,866	8,537	91.5%
Cytokine & CAM	TALTZ	171	273	102	59.6%
Respiratory Agents	TRIKAFTA	178	238	60	33.7%
HIV	EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	2,717	3,585	868	31.9%
Cytokine & CAM	STELARA	482	616	134	27.8%
Asthma and COPD Agents	ALBUTEROL SULFATE HFA	123,928	157,633	33,705	27.2%
Pulmonary Arterial Hypertension	UPTRAVI	51	63	12	23.5%
Asthma and COPD Agents	BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE	8,916	11,005	2,089	23.4%
Antivirals	MAVYRET	1,770	1,443	(327)	-18.5%
HIV	GENVOYA	595	424	(171)	-28.7%



Top 25 Drugs by Cost – Summary of Utilization

• Of the top 25 drugs from 2021 to 2023

- 22 drugs had an increase in client utilization
 - The drugs with the greatest percent increase in clients includeSkyrizi Pen, Sublocade, Rinvoq, Dupixent, Biktarvy, Victoza, Jardiance, Taltz, Trikafta, emtricitabine/tenofovir disoproxil fumarate, Stelara, albuterol sulfate HFA, Uptravi, and budesonide/formoterol fumarate dihydrate
- 3 drugs had a decrease in client utilization
 - > The drugs with a decrease include Tivicay, Mavyret, and Genvoya
- The number of clients utilizing a drug each year ranges from 63 to 157,633



Takeaways & Discussion

HCA uses drug utilization data to manage the pharmacy benefit

- Trends in prescribing patterns
- Management strategies for drug classes with rebates
- Ensure appropriate use with clinical policies
- HCA plans to continue bringing these presentations to the P&T DUR Board

